Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 117 articles:
HTML format



Single Articles


    December 2022
  1. FOUSEKIS FS, Katsanos KH, Popovic DD
    Translation and validation of questionnaires: necessary processes for inflammatory bowel disease studies reliability.
    Eur J Gastroenterol Hepatol. 2022;34:1201-1202.
    PubMed    


  2. NARULA N, Wong ECL, Moayyedi P, Reinisch W, et al
    Pilot study of an elimination diet in adults with mild to moderate Crohn's disease.
    Eur J Gastroenterol Hepatol. 2022;34:1210-1219.
    PubMed     Abstract available


    November 2022
  3. FISKE J, Liu E, Limdi JK, Conley TE, et al
    Safety and effectiveness of ustekinumab in elderly Crohn's disease patients.
    Eur J Gastroenterol Hepatol. 2022;34:1132-1139.
    PubMed     Abstract available


  4. EBERL A, Qadri S, Saavalainen P, Sipponen T, et al
    Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022;34:1125-1131.
    PubMed     Abstract available


    October 2022
  5. MARTINHO-GRUEBER M, Kapoglou I, Bravo F, Sarraj R, et al
    Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease.
    Eur J Gastroenterol Hepatol. 2022 Oct 26. pii: 00042737-990000000-00082.
    PubMed     Abstract available


  6. MOENS A, Alsoud D, Verstockt B, Sabino J, et al
    Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
    Eur J Gastroenterol Hepatol. 2022;34:1015-1020.
    PubMed     Abstract available


  7. TEN BOKKEL HUININK S, de Jong DC, Nieboer D, Thomassen D, et al
    Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2022;34:983-992.
    PubMed     Abstract available


    September 2022
  8. CASSINOTTI A, Mezzina N, De Silvestri A, Di Paolo D, et al
    Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison study.
    Eur J Gastroenterol Hepatol. 2022 Sep 23. pii: 00042737-990000000-00076.
    PubMed     Abstract available


  9. EBERL A, Qadri S, Saavalainen P, Sipponen T, et al
    Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022 Sep 12. pii: 00042737-990000000-00059.
    PubMed     Abstract available


  10. THEODORAKI E, Orfanoudaki E, Petroulaki E, Foteinogiannopoulou K, et al
    Active smoking is associated with the development of adverse events of biological therapy in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022 Sep 12. pii: 00042737-990000000-00073.
    PubMed     Abstract available


  11. PAUPARD T, Gonzalez F, Caron B, Siproudhis L, et al
    Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study.
    Eur J Gastroenterol Hepatol. 2022 Sep 12. pii: 00042737-990000000-00067.
    PubMed     Abstract available


  12. ROBERTS CM, Gamwell KL, Baudino MN, Edwards CS, et al
    Illness stigma, body image dissatisfaction, thwarted belongingness and depressive symptoms in youth with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022;34:919-924.
    PubMed     Abstract available


    August 2022
  13. TURSI A, Lopetuso LR, Vetrone LM, Gasbarrini A, et al
    SARS-CoV-2 infection as a potential trigger factor for de novo occurrence of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022;34:883-884.
    PubMed    


  14. WEWER MD, Karstensen JG, Burisch J
    Endoscopic small bowel balloon dilations in patients with Crohn's disease: a Danish nationwide cohort study, 1997-2015.
    Eur J Gastroenterol Hepatol. 2022;34:831-837.
    PubMed     Abstract available


    July 2022
  15. ZHU F, Qin Y, Wang Y, Zhang F, et al
    Critical roles of RGS16 in the mucosal inflammation of ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2022 Jul 14. pii: 00042737-990000000-00034.
    PubMed     Abstract available


  16. DIPASQUALE V, Pellegrino S, Ventimiglia M, Cucinotta U, et al
    Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease.
    Eur J Gastroenterol Hepatol. 2022 Jul 14. pii: 00042737-990000000-00036.
    PubMed     Abstract available


  17. GIRI S, Ingawale S
    Use of restrictive iron transfusion strategy in inflammatory bowel disease: one size does not fit all.
    Eur J Gastroenterol Hepatol. 2022;34:807.
    PubMed    


  18. GROVA M, Crispino F, Maida M, Macaluso FS, et al
    Authors' reply to 'Use of restrictive iron transfusion strategy in IBD: one size does not fit all'.
    Eur J Gastroenterol Hepatol. 2022;34:808.
    PubMed    


    April 2022
  19. FERRANTE M, Schirbel A, Pierik MJ, Haas T, et al
    Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study.
    Eur J Gastroenterol Hepatol. 2022 Apr 8. pii: 00042737-990000000-00016.
    PubMed     Abstract available


  20. GOMOLLON F, Gisbert JP, Guerra I, Plaza R, et al
    Clinical characteristics and prognostic factors for Crohn's disease relapses using natural language processing and machine learning: a pilot study.
    Eur J Gastroenterol Hepatol. 2022;34:389-397.
    PubMed     Abstract available


  21. BODINI G, Demarzo MG, Djahandideh A, Ziola S, et al
    Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques.
    Eur J Gastroenterol Hepatol. 2022;34:382-388.
    PubMed     Abstract available


  22. HOWARD G, Weiner D, Bar-Or I, Levine A, et al
    Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children.
    Eur J Gastroenterol Hepatol. 2022;34:372-374.
    PubMed     Abstract available


    March 2022
  23. SMITH RL, Taylor KM, Friedman AB, Gibson DJ, et al
    Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00008.
    PubMed     Abstract available


  24. CHUCK W, Shadbolt BF, Nordin F, Subramaniam K, et al
    BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor-alpha inhibitors.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00002.
    PubMed     Abstract available


  25. YOSHIDA A, Kimura K, Morizane T, Ueno F, et al
    Predictor of primary response to antitumor necrosis factor-alpha therapy for inflammatory bowel disease: a single-center observational study.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00007.
    PubMed     Abstract available


  26. LEI N, Kong P, Chen S, Wang Q, et al
    Upregulated NORAD is implicated in apoptosis, inflammation, and oxidative stress in ulcerative colitis through the nuclear factor-kappaappaB signaling.
    Eur J Gastroenterol Hepatol. 2022 Mar 29. pii: 00042737-990000000-00004.
    PubMed     Abstract available


  27. POO S, Sriranganathan D, Segal JP
    Network meta-analysis: efficacy of treatment for acute, chronic, and prevention of pouchitis in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2022 Mar 9. pii: 00042737-900000000-97083.
    PubMed     Abstract available


  28. DAWRA S, Manrai M, Kumar A, Kumar S, et al
    Hyperbaric oxygen therapy in inflammatory bowel disease: a systemic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2022;34:359-360.
    PubMed    


  29. TUN GSZ, Robinson K, Marshall L, Wright A, et al
    The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab.
    Eur J Gastroenterol Hepatol. 2022;34:295-301.
    PubMed     Abstract available


    February 2022
  30. FALLING CL, Stebbings S, David Baxter G, Siegel CA, et al
    Somatosensory assessments in patients with inflammatory bowel disease: a cross-sectional study examining pain processing pathways and the role of multiple patient factors.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97087.
    PubMed     Abstract available


    January 2022
  31. GROVA M, Crispino F, Maida M, Renna S, et al
    Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease: a real world experience.
    Eur J Gastroenterol Hepatol. 2022 Jan 31. pii: 00042737-900000000-97093.
    PubMed     Abstract available


  32. GIANNOS P, Triantafyllidis KK, Giannos G, Kechagias KS, et al
    SPP1 in infliximab resistant ulcerative colitis and associated colorectal cancer: an analysis of differentially expressed genes.
    Eur J Gastroenterol Hepatol. 2022 Jan 31. pii: 00042737-900000000-97092.
    PubMed     Abstract available


  33. KRUIS W, Leifeld L
    Response to: Malignancy associated to perianal Chrohn s fistula - a challenge for more clinical research.
    Eur J Gastroenterol Hepatol. 2022;34:9-10.
    PubMed    


  34. ADEGBOLA SO, Sarafian M, Sahnan K, Pechlivanis A, et al
    Lack of anti-TNF drugs levels in fistula tissue - a reason for nonresponse in Crohn's perianal fistulating disease?
    Eur J Gastroenterol Hepatol. 2022;34:18-26.
    PubMed     Abstract available


    December 2021
  35. THOMAS PWA, Smits LJT, Te Groen M, West RL, et al
    De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation.
    Eur J Gastroenterol Hepatol. 2021 Dec 30. pii: 00042737-900000000-97101.
    PubMed     Abstract available


  36. GUILLO L, Bonnaud G, Nahon S, Caron B, et al
    French experience with telemedicine in inflammatory bowel disease: a patients and physicians survey.
    Eur J Gastroenterol Hepatol. 2021 Dec 3. pii: 00042737-900000000-97115.
    PubMed     Abstract available


  37. GOODDAY SM, Travis S, Walsh A, Friend SH, et al
    Stress-related consequences of the coronavirus disease 2019 pandemic on symptoms of Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33:1511-1516.
    PubMed     Abstract available


  38. ADEGBOLA SO, Sarafian M, Sahnan K, Ding NS, et al
    Differences in amino acid and lipid metabolism distinguish Crohn's from idiopathic/cryptoglandular perianal fistulas by tissue metabonomic profiling and may offer clues to underlying pathogenesis.
    Eur J Gastroenterol Hepatol. 2021;33:1469-1479.
    PubMed     Abstract available


  39. SINGH AK, Kumar-M P, Sharma V
    Hyperbaric oxygen therapy for ulcerative colitis: conflicting evidence from randomized trials.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  40. TURSI A
    Performances of anti-TNFalpha antibodies as long-term maintenance therapy for ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  41. MOURAD FH, Leong RW, Kariyawasam VC
    Early thiopurine maintenance and reduced colectomy rate in ulcerative colitis: fact or fiction?
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  42. NG A
    Mind the lipids: hyperlipidaemia resultant from JAK inhibitor use in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  43. NG A
    Early thiopurine maintenance and reduced colectomy rate in ulcerative colitis: fact or fiction?
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  44. NG A
    The efficacy of tumour necrosis factor-alpha antagonists in maintenance therapy for ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  45. GARRIDO I, Santos AL, Lopes J, Lopes S, et al
    "Hepatotoxicity in inflammatory bowel disease: mesalazine, the forgotten drug".
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  46. DING NS, Lee T, Bettenworth D, Cleynen I, et al
    Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): results from an international survey.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  47. INNOCENTI T, Roselli J, Lynch EN, Apolito P, et al
    Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  48. VIOLA A, Muscianisi M, Voti RL, Costantino G, et al
    Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  49. HILARY K, Carthage M, Jawad R, Karen B, et al
    Lost in words? The readability of medication information sheets in commonly used medication in inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  50. NG A
    Histological subtypes of perianal fistula-associated malignancies in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  51. SILVA MENDES S, Ferreira P, Antunes P, Goncalves M, et al
    Validation of the IBD-Disk in a Portuguese cohort.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  52. LI X, Wang Y, Ge T, Xiao Y, et al
    Henoch-Schonlein purpura associated with infliximab therapy for pediatric Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  53. HANZEL J, Kozelj M, Spes Hlastec A, Kurent T, et al
    Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  54. TEN BOKKEL HUININK S, Biemans V, Duijvestein M, Pierik M, et al
    Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  55. PIAZZOLLA M, Marmo R, Terracciano F, Perri F, et al
    Asymptomatic retention of fragmented small bowel capsule endoscopy retrieved by retrograde double-balloon enteroscopy in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  56. SALVATORI S, Marafini I, Monteleone G
    Paradoxical hidradenitis suppurativa in Crohn's disease patients receiving infliximab: a case report and review of literature.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  57. LI T, Gao L, Cao L, Guo Z, et al
    Changes in disease behaviour and location and factor analysis in patients with Crohn's disease undergoing repeated-resections.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  58. CROCETTI E, Bergamaschi W, Russo AG
    Population-based incidence and prevalence of inflammatory bowel diseases in Milan (Northern Italy), and estimates for Italy.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  59. WALSHE M, Borowski K, Boland K, Rho S, et al
    Ustekinumab induction concentrations are associated with clinical and biochemical outcomes at week 12 of treatment in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


    November 2021
  60. YAO J, Gao R, Luo M, Li D, et al
    Long noncoding RNA KIF9-AS1 promotes cell apoptosis by targeting the microRNA-148a-3p/suppressor of cytokine signaling axis in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Nov 8. pii: 00042737-900000000-97127.
    PubMed     Abstract available


  61. TURSI A, Florio T, Tiano M
    Successful treatment of concomitant Crohn's disease and psoriasis with risankizumab.
    Eur J Gastroenterol Hepatol. 2021;33:1462-1464.
    PubMed    


  62. PUTIGNANI L, Oliva S, Isoldi S, Del Chierico F, et al
    Fecal and mucosal microbiota profiling in pediatric inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2021;33:1376-1386.
    PubMed     Abstract available


    October 2021
  63. SHAMSEYA AM, Hussein WM, Elnely DA, Adel F, et al
    Serum matrix metalloproteinase-9 concentration as a marker of disease activity in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Oct 20. pii: 00042737-900000000-97135.
    PubMed     Abstract available


  64. VELAYOS JIMENEZ B, Del Olmo Martinez L, Macho Conesa A, Fernandez Salazar L, et al
    Should the birth month be considered as one of the possible environmental risk factors in the pathogenesis of inflammatory bowel disease?
    Eur J Gastroenterol Hepatol. 2021;33:1332.
    PubMed    


  65. GREENER T, Boland K, Milgrom R, Ben-Bassat O, et al
    Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients.
    Eur J Gastroenterol Hepatol. 2021;33:1274-1279.
    PubMed     Abstract available


    August 2021
  66. BAMIAS G, Kokkotis G, Christidou A, Christodoulou DK, et al
    The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD.
    Eur J Gastroenterol Hepatol. 2021 Aug 16. pii: 00042737-900000000-97160.
    PubMed     Abstract available


  67. KARIMI N, Sechi AJ, Harb M, Sawyer E, et al
    The effect of a nurse-led advice line and virtual clinic on inflammatory bowel disease service delivery: an Australian study.
    Eur J Gastroenterol Hepatol. 2021 Aug 16. pii: 00042737-900000000-97158.
    PubMed     Abstract available


  68. CAPRIOLI F, Daperno M, Bravata I, Brigido A, et al
    Who are the patients with Crohn's disease unsuitable to receive an anti-TNFalpha therapy? Results from a survey of Italian physicians and literature review.
    Eur J Gastroenterol Hepatol. 2021;33:1082-1090.
    PubMed     Abstract available


  69. GONG W, Guo K, Zheng T, Xie H, et al
    JINLING (Judicious INdex of Luminal INflammation Grade) score, an effective indicator to assess inflammation severity in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2021;33:1049-1054.
    PubMed     Abstract available


    July 2021
  70. SMITH RL, Taylor KM, Friedman AB, Su HY, et al
    Interrater reliability of the assessment of disease activity by gastrointestinal ultrasound in a prospective cohort of patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Jul 30. pii: 00042737-900000000-97173.
    PubMed     Abstract available


  71. GONZALEZ-PARTIDA I, Martinez-Lozano H, Gonzalez-Lois C, Peligros I, et al
    Histological inflammatory activity can predict endoscopic relapse in patients with ulcerative colitis who have achieved mucosal healing.
    Eur J Gastroenterol Hepatol. 2021 Jul 30. pii: 00042737-900000000-97168.
    PubMed     Abstract available


  72. ORFANOUDAKI E, Drygiannakis I, Theodoraki E, Foteinogiannopoulou K, et al
    Real-life utility and diagnostic accuracy of a home-performed fecal calprotectin test to predict endoscopic activity in patients with inflammatory bowel disease under maintenance treatment with adalimumab.
    Eur J Gastroenterol Hepatol. 2021 Jul 19. pii: 00042737-900000000-97178.
    PubMed     Abstract available


  73. CORTEGOSO VALDIVIA P, Elosua A, Houdeville C, Pennazio M, et al
    Clinical feasibility of panintestinal (or panenteric) capsule endoscopy: a systematic review.
    Eur J Gastroenterol Hepatol. 2021;33:949-955.
    PubMed     Abstract available


  74. NERI B, Scarozza P, Giannarelli D, Sena G, et al
    Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2021;33:977-982.
    PubMed     Abstract available


  75. LIVNE M, Amitai MM, Klang E, Ben Horin S, et al
    Qualitative sonographic assessment of transmural ileal inflammation in Crohn's disease: a comparison with MRI activity score.
    Eur J Gastroenterol Hepatol. 2021;33:961-966.
    PubMed     Abstract available


    June 2021
  76. RICHTER V, Bermont A, Cohen DL, Broide E, et al
    Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience.
    Eur J Gastroenterol Hepatol. 2021 Jun 29. pii: 00042737-900000000-97186.
    PubMed     Abstract available


  77. ATTAUABI M, Vind I, Pedersen G, Bendtsen F, et al
    Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study.
    Eur J Gastroenterol Hepatol. 2021 Jun 7. pii: 00042737-900000000-97194.
    PubMed     Abstract available


  78. LLAO J, Masnou H, Romero C, Bargallo A, et al
    Noninvasive assessment of liver fibrosis in Crohn's disease patients exposed to methotrexate.
    Eur J Gastroenterol Hepatol. 2021;33:794-798.
    PubMed     Abstract available


    May 2021
  79. RIZOS ED, Antonogiannaki EM, Chatzidakis A, Kallieri M, et al
    Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97199.
    PubMed     Abstract available


  80. GATOPOULOU A, Christodoulou DK, Katsanos KH, Bakos D, et al
    Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Gree
    Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97217.
    PubMed     Abstract available


  81. VOHRA I, Attar B, Haghbin H, Mutneja H, et al
    Incidence and risk factors for 30-day readmission in ulcerative colitis: nationwide analysis in biologic era.
    Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97210.
    PubMed     Abstract available


  82. ANGELINO G, Cifaldi C, Zangari P, Di Cesare S, et al
    Gastric cancer, inflammatory bowel disease and polyautoimmunity in a 17-year-old boy: CTLA-4 deficiency successfully treated with Abatacept.
    Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97208.
    PubMed     Abstract available


  83. VAN GENNEP S, Gielen ME, Rietdijk ST, de Boer NKH, et al
    Work productivity loss is determined by fatigue and reduced quality of life in employed inflammatory bowel disease patients: a prospective multicentre cohort study.
    Eur J Gastroenterol Hepatol. 2021 May 3. doi: 10.1097/MEG.0000000000002178.
    PubMed     Abstract available


  84. VIGLIO A, Lenti MV, Vanoli A, Di Sabatino A, et al
    Rectal neuroendocrine cell proliferation in a patient with ulcerative colitis treated with adalimumab.
    Eur J Gastroenterol Hepatol. 2021;33:766-768.
    PubMed    


  85. TURSI A, Mocci G, Lorenzetti R, Allegretta L, et al
    Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
    Eur J Gastroenterol Hepatol. 2021;33:670-679.
    PubMed     Abstract available


  86. FREITAS M, Curdia Goncalves T, Boal Carvalho P, Dias de Castro F, et al
    From terminal ileitis to Crohn's disease: how capsule endoscopy is crucial to diagnosis.
    Eur J Gastroenterol Hepatol. 2021;33:631-638.
    PubMed     Abstract available


    April 2021
  87. SINGH AK, Jha DK, Jena A, Kumar-M P, et al
    Hyperbaric oxygen therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2021 Apr 19. doi: 10.1097/MEG.0000000000002164.
    PubMed     Abstract available


  88. CORREIA JP, Ponte AI, Silva JC, Gomes AC, et al
    Mesalazine-induced acute pancreatitis: a rare adverse reaction but with important therapeutic implications in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;33:595.
    PubMed    


  89. GONELLA F, Massucco P, Daperno M, Mineccia M, et al
    Ulcerative enteritis. How the extension of ulcerative colitis to small bowel may jeopardize postcolectomy course: a case report and literature review.
    Eur J Gastroenterol Hepatol. 2021;33:589-594.
    PubMed     Abstract available


  90. GOMES C, Pinho R, Ponte A, Silva JC, et al
    Patient's perspective on the implementation of measures to contain the SARS-CoV-2 pandemic in a Portuguese Gastroenterology Department.
    Eur J Gastroenterol Hepatol. 2021;33:527-532.
    PubMed     Abstract available


  91. TAMILARASAN AG, Krishnananthan T
    Faecal microbiota transplantation: what's beyond Clostridium difficile infection?
    Eur J Gastroenterol Hepatol. 2021;33:487-494.
    PubMed     Abstract available


    March 2021
  92. CROOKS B, Misra R, Arebi N, Kok K, et al
    The dietary practices and beliefs of people living with older-onset inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Mar 18. pii: 00042737-900000000-97269.
    PubMed     Abstract available


  93. FERNANDES SR, Serrazina J, Rodrigues IC, Bernardo S, et al
    Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97288.
    PubMed     Abstract available


  94. KARIYAWASAM VC, Mourad FH, Mitrev N, Paramsothy S, et al
    Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97273.
    PubMed     Abstract available


  95. SCHARRER S, Kutschera M, Weseslindtner L, Primas C, et al
    Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;33:443-447.
    PubMed     Abstract available


  96. CANCADO GGL, Nardelli MJ, Gouthier MAD
    Adalimumab-induced leukocytoclastic vasculitis in a Crohn's disease patient.
    Eur J Gastroenterol Hepatol. 2021;33:453.
    PubMed    


  97. SHARMA V, Verma S, Kumar-M P, Mandavdhare HS, et al
    Serial measurements of faecal calprotectin may discriminate intestinal tuberculosis and Crohn's disease in patients started on antitubercular therapy.
    Eur J Gastroenterol Hepatol. 2021;33:334-338.
    PubMed     Abstract available


    February 2021
  98. KYRIAKOS N, Papaefthymiou A, Giakoumis M, Galanopoulos M, et al
    Prevalence of inflammatory bowel disease in young Greek Army male recruits from 2006 to 2018: a 13-year retrospective study from a tertiary center.
    Eur J Gastroenterol Hepatol. 2021 Feb 26. pii: 00042737-900000000-97290.
    PubMed     Abstract available


  99. LOVERO R, Losurdo G, La Fortezza RF, Terracciano F, et al
    Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;32:201-207.
    PubMed     Abstract available


  100. MANTAKA A, Tsoukali E, Fragaki M, Karmiris K, et al
    Reply to the letter to the Editor: 'The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease'.
    Eur J Gastroenterol Hepatol. 2021;32:300-302.
    PubMed    


    January 2021
  101. KOUMAKI D, Machaira A, Katoulis AC, Bitados P, et al
    Mucocutaneous manifestations in patients with inflammatory bowel disease: a decade study from a Greek cohort.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97312.
    PubMed     Abstract available


  102. UNAL NG, Oruc N, Tomey O, Omer Ozutemiz A, et al
    Malnutrition and sarcopenia are prevalent among inflammatory bowel disease patients with clinical remission.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97311.
    PubMed     Abstract available


  103. MAGRI S, Chessa L, Demurtas M, Cabras F, et al
    Review article: safety of new biologic agents for inflammatory bowel disease in the liver.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97310.
    PubMed     Abstract available


  104. STRAATMIJER T, van Gennep S, Duijvestein M, Ponsioen CIJ, et al
    Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


  105. FIGUEREDO CM, Nunes JGR, Mello-Neto JM, Carvalho AT, et al
    Higher salivary expression of S100A12 in patients with ulcerative colitis and chronic periodontitis.
    Eur J Gastroenterol Hepatol. 2021;33:116-117.
    PubMed    


    November 2020
  106. WEISLINGER L, Guillo L, D'Amico F, Danese S, et al
    Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002008.
    PubMed     Abstract available


  107. LYUTAKOV I, Lozanov V, Sugareva P, Valkov H, et al
    Serum 7-alfa-hydroxy-4-cholesten-3-one and fibroblast growth factor-19 as biomarkers diagnosing bile acid malabsorption in microscopic colitis and inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Nov 10. doi: 10.1097/MEG.0000000000001925.
    PubMed     Abstract available


  108. LYU L, Chen D, Yu M, Yang Y, et al
    The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020;32:1480-1481.
    PubMed    


    October 2020
  109. GILISSEN LPL, Tajzai R, Romberg M, Pierik M, et al
    The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1097/MEG.0000000000001980.
    PubMed     Abstract available


  110. ROMEO S, Neri B, Mossa M, Calabrese E, et al
    Finger clubbing in inflammatory bowel disease: association with upper small bowel lesions and need of surgery in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1097/MEG.0000000000001966.
    PubMed     Abstract available


  111. KJAERGAARD S, Jensen TSR, Feddersen UR, Bindslev N, et al
    Decreased number of colonic tuft cells in quiescent ulcerative colitis patients.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001959.
    PubMed     Abstract available


  112. MOOSVI Z, Duong J, Bechtold ML, Nguyen DL, et al
    Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001944.
    PubMed     Abstract available


  113. BHAMBHVANI HP, Zamora A
    Deep learning enabled classification of Mayo endoscopic subscore in patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001952.
    PubMed     Abstract available


    September 2020
  114. LOPETUSO LR, Corbi M, Scaldaferri F, Petito V, et al
    Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment.
    Eur J Gastroenterol Hepatol. 2020 Sep 23. doi: 10.1097/MEG.0000000000001933.
    PubMed     Abstract available


  115. VELLOPOULOU K, Stefanou G, Tzanetakos C, Boubouchairopoulou N, et al
    Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece.
    Eur J Gastroenterol Hepatol. 2020 Sep 23. doi: 10.1097/MEG.0000000000001916.
    PubMed     Abstract available


    May 2020
  116. OZKAN E, Basaranoglu M
    Recurrent 'gloves and socks' distribution with bullous eruptions after adalimumab and infliximab treatment in a patient with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2020;32:666-667.
    PubMed    


    April 2020
  117. GUNEY M, Basaranoglu M
    A patient with Crohn's disease during remission by biological agent treatment developed active pulmonary tuberculosis and determining the eating habits.
    Eur J Gastroenterol Hepatol. 2020;32:541-542.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: